Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 7/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.36 |
| ▸ | MGLL | Q99685 | 2/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.33 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL645874 | 0.89 | KDM4C (0.43) | HTR6KDM4CSIRT1MGLL | |
| SCHEMBL14299175 | 0.80 | KDM4C (0.49) | HTR6KDM4CSIRT1SIRT2 | |
| SCHEMBL10110856 | 0.79 | HTR6 (0.40) | HTR6KDM4C | |
| Hydrochloric Acid SCHEMBL641981 | 0.78 | HTR6 (0.40) | HTR6KDM4CDRD1 | |
| SCHEMBL643588 | 0.76 | HTR6 (0.67) | HTR6KDM4C | |
| SCHEMBL643589 | 0.76 | HTR6 (0.67) | HTR6KDM4C | |
| SCHEMBL13288491 | 0.76 | HTR6 (0.40) | HTR6KDM4CDRD1 | |
| Hydrochloric Acid SCHEMBL642292 | 0.75 | HTR6 (0.35) | HTR6KDM4CDRD1 | |
| SCHEMBL642955 | 0.74 | KDM4C (0.51) | HTR6KDM4CMGLL | |
| SCHEMBL643834 | 0.74 | KDM4C (0.51) | HTR6KDM4CMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365494-B2 | Process for synthesis of amino-methyl tetralin derivatives | ROCHE PALO ALTO LLC (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365494-B2 | Process for synthesis of amino-methyl tetralin derivatives | ROCHE PALO ALTO LLC (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365494-B2 | Process for synthesis of amino-methyl tetralin derivatives | ROCHE PALO ALTO LLC (US) | 2016-06-14 | — | — | US | disclosed |
| EP-2379491-B1 | Process for synthesis of amino-methyl tetraline derivatives | HOFFMANN LA ROCHE (CH) | 2013-03-20 | — | — | EP | disclosed |
| US-20120323040-A1 | PROCESS FOR SYNTHESIS OF AMINO-METHYL TETRALIN DERIVATIVES | DURKIN KIERAN (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120323040-A1 | PROCESS FOR SYNTHESIS OF AMINO-METHYL TETRALIN DERIVATIVES | DURKIN KIERAN (US) | 2012-12-20 | — | — | US | disclosed |
| US-8119842-B2 | Process for synthesis of amino-methyl tetralin derivatives | Roche Palo Alto LLP (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119842-B2 | Process for synthesis of amino-methyl tetralin derivatives | Roche Palo Alto LLP (US) | 2012-02-21 | — | — | US | disclosed |
| EP-2379491-A1 | PROCESS FOR SYNTHESIS OF AMINO-METHYL TETRALINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010069778-A1 | PROCESS FOR SYNTHESIS OF AMINO-METHYL TETRALINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010069778-A1 | PROCESS FOR SYNTHESIS OF AMINO-METHYL TETRALINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-24 | — | — | WO | disclosed |
| US-20100160682-A1 | PROCESS FOR SYNTHESIS OF AMINO-METHYL TETRALIN DERIVATIVES | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
| US-20100160682-A1 | PROCESS FOR SYNTHESIS OF AMINO-METHYL TETRALIN DERIVATIVES | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160682-A1 | PROCESS FOR SYNTHESIS OF AMINO-METHYL TETRALIN DERIVATIVES | PKN2, CCND2, PRMT1 | HTR6 1893/4885KDM4C 1363/4885SIRT1 2751/4885 |
| US-20120323040-A1 | PROCESS FOR SYNTHESIS OF AMINO-METHYL TETRALIN DERIVATIVES | PKN2, CCND2, PRMT1 | HTR6 1965/4885KDM4C 1334/4885SIRT1 2744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.